Multiple studies have investigated the possible involvement—also in MASLD pathophysiology—of molecular mechanisms initially identified as exclusive of bone disease, with a focus on receptor activator of NF-κB (RANK), receptor activator of NF-κB ligand (RANKL), and osteoprotegerin (OPG). Here, TNFSF11 is linked to metabolic dysfunction-associated steatotic liver disease.